研究業績（原著論文のみ）/ Publications(Original Articles only)

• 2022-2023
• 2020-2021
• 2018-2019

• 2016-2017
• 2015-2014
• 2013-2012
• 2011-2006

2015年度

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K. Oncotarget. 2015.12 [Epub ahead of print]

Discovery of a good responder subtype of esophageal squamous cell carcinoma with cytotoxic T-lymphocyte signatures activated by chemoradiotherapy.
Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, Nishimura T, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Narumi K, Aoki K, Fujii S, Ochiai A, Yoshida T, Muto M, Yamada Y, Sasaki H. PLoS One. 2015 Dec 1;10(12):e0143804.

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
Togashi Y, Mizuuchi H, Tomida S, Terashima M, Hayashi H, Nishio K, Mitsudomi T. Lung Cancer. 2015 Dec;90(3):590-7.

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K. PLoS One. 2015 Nov 16;10(11):e0143132.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision-making in lung cancer.
Takeda M, Sakai K, Terashima M, Kaneda H, Hayashi H, Tanaka K, Okamoto K, Takahama T, Yoshida T, Iwasa T, Shimizu T, Nonogase Y, Kudo K, Tomida S, Mitsudomi T, Saigo K, Ito A, Nakagawa K, Nishio K. Ann Oncol. 2015 Dec;26(12):2477-82.

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, and Mitsudomi T. Scientific Reports. 2015 Sep 24;5:14447. doi:10.1038/srep14447.

Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: Identification of a recurrent p.P25L mutation in KRT5 in four affected family members.
Nagai H, Oiso N, Tomida S, Sakai K, Fujiwara S, Nakamachi Y, Kawano S, Kawada A, Nishio K, Nishigori C. Br J Dermatol. 2015 [Epub ahead of print]

Randomized phase II study of adjuvant chemotherapy with long-term S-1 versus cisplatin+S-1 in completely resected stage II-IIIA non-small cell lung cancer.
Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K. Clin Cancer Res. 2015 Dec 1;21(23):5245-52.

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T. Oncotarget. 2015 Oct 13;6(31):30850-8. doi: 10.18632/oncotarget.5068.

Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma.
Yoshioka Y, Togashi Y, Chikugo T, Kogita A, Terashima M, Mizukami T, Hayashi H, Sakai K, de Velasco, MA, Tomida, S, Fujita Y, Tokoro T, Ito A, Okuno K, Nishio K. Cancer. 2015 Dec 15;121(24):4359-68.

The pan-HER family tyrosine kinase inhibitor Afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K. Oncotarget. 2015 Oct 20;6(32):33602-11. doi: 10.

EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib and neratinib as compared with first or third generation TKIs.
Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T. Clin Cancer Res. 2015 Dec 1;21(23):5305-13.

Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells.
Suzuki T, Ishibashi K, Yumoto A, Nishio K, Ogasawara Y.Oncol Lett. 2015 Aug;10(2):805-809.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, Velasco MA, Sakai K, Fujita Y, Tomida S, Eguchi-Nakajima T, Boku N, Nishio K. Int J Oncol. 2015 Jun 16. doi: 10.3892/ijo.2015.3050.47(2):499-505.

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, J?nne PA, Nakagawa K. Oncogene. 2015 May 11.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer.
Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Bannno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22.

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K, Takeda H, Nakajima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y. Oncotarget. 2015 Aug 28;6(25):21636-44.

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Cancer Sci. 2015 Jul;106(7):883-90.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K. PLoS One. 2015 May 8;10(5):e0121891.

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H. J Transl Med. 2015 May 8;13(1):150.

Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.
Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T. PLoS One. 2015 Apr 14;10(4):e0123901.

Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model.
Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H. Asian Pac J Cancer Prev. 2015;16(5):1827-31.

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.
Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K. Anticancer Res. 2015 Mar;35(3):1683-9.

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K. Br J Cancer. 2015 Mar 3;112(5):819-24.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashim M, deVelasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K. Lung Cancer. 2015 Apr;88(1):16-23.

Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K. Biochem Biophys Res Commun. 2015 Feb 27;458(1):52-6.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K. Cancer Lett. 2015.1 356(2 Pt B): 819-27.

Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T1, Kurita T, Nishio K, Tsukada J, Hachisuga T, Morimoto Y, Iwai Y, Izumi H. Cancer Sci. 2015 Apr;106(4):359-66.

2014年度

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Nishio K, et al. Springerplus. 2015 Jan 5;4:7.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797.Epub 2014 Dec 15.

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
Banno E, Togashi Y, Kobayashi Y, Hayashi H, Mitsudomi T, Nishio K. Anticancer Res. 2015 Apr;35(4):2005-8.

A Supramolecular Substance, [2] Rotaxane, Induces Apoptosis in Human Molt-3 Acute Lymphoblastic Leukemia Cells.
Kimura M, Makio K, Hara K, Hiruma W, Fujita Y, Takata T, Nishio K, Ono N. Drug Res, 2015 Nov; 65(11):614-6.

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K. Oncotarget. 2014 Dec 15;5(23):11847-56.

Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding.
Shiotani A, Murao T, Fujita Y, Fujimura Y, Sakakibara T, Nishio K, Haruma K. J Gastroenterol Hepatol. 2014 Dec;29 Suppl 4:47-52. doi: 10.1111/jgh.12770.

MEK inhibitor for gastric cancer with MEK1 gene mutations.
Shunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, Akihiro Kogita, Takuro Mizukami, Yoichi Sakamoto, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco A De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Takushi Yasuda, Yoshifumi Takeyama, Kiyotaka Okuno, and Kazuto Nishio. Mol Cancer Ther. 2014 Sep 24. pii: molcanther.0429.2014. 13(12): 3098-106, 2014.12

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter.
Sakai K, Takeda M, Okamoto I, Nakagawa K, Nishio K. Oncol Lett. 2015 Jan;9(1):405-410.

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.
Kazuko Sakai, Shinsuke Kazama, Yuzo Nagai, Koji Murono, Toshiaki Tanaka, Soichiro Ishihara, Eiji Sunami, Shuta Tomida, Kazuto Nishio, Toshiaki Watanabe. Oncotarget. 2014 Oct 30;5(20):9641-9.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
Maki Tanioka, Kazuko Sakai, Tamotsu Sudo, Toshiko Sakuma, Kajimoto Kazuyoshi, Koichi Hirokaga, Shintaro Takao, Shunichi Negoro, Hironobu Minami, Kazuhiko Nakagawa, Kazuto Nishio. Breast Cancer Res Treat. 2014 Oct;147(3):513-25. doi: 10.1007/s10549-014-3121-5. Epub 2014 Sep 9.

Inhibition of β-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small cell lung cancer with a T790M mutation.
Yosuke Togashi, Hidetoshi Hayashi, Masato Terashima, Marco A de Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Kazuhiko Nakagawa, Kazuto Nishio. J Thorac Oncol, 2014. 2015 Jan;10(1):93-101.>

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.
Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, and Nishio K. Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014.

Randomized Phase II Trial of Nimotuzumab plus Irinotecan vs. Irinotecan Alone as Second-line Therapy for Patients with Advanced Gastric Cancer.
Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Yasutsuna Sasaki, Se Hoon Park, Yoshito Komatsu, Hirofumi Yasui, Tae-You Kim, Kensei Yamaguchi, Nozomu Fuse, Yasuhide Yamada, Takashi Ura, Si-Young Kim, Masaki Munakata, Soh Saitoh, Kazuto Nishio, Satoshi Morita, Eriko Yamamoto, Qingwei Zhang, Jung-mi Kim, Yeul Hong Kim, Yuh Sakata. Gastric Cancer. 2015 Oct;18(4):824-32.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
Akihiro Kogita, Yosuke Togashi1, Hidetoshi Hayashi, Shunsuke Sogabe, Masato Terashima, Marco A. de Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Yoshifumi Takeyama, Kiyotaka Okuno, Kazuhiko Nakagawa and Kazuto Nishio. Int J Oncol. 2014 Oct;45(4):1430-6. doi: 10.3892/ijo.2014.2574. Epub 2014 Aug 1.

Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa and Kazuto Nishio. Cancers 2014, 6(3), 1540-1552;

Clinical utility of erlotinib for the treatment of non-small cell lung cancer in Japanese patients: current evidence.
Yosuke Togashi, Hidetoshi Hayashi, Kazuhiko Nakagawa, and Kazuto Nishio Drug Des Devel Ther. 2014 Jul 31;8:1037-46. doi: 10.2147/DDDT.S50358. eCollection 2014.

Guidance for peptide vaccines for the treatment of cancer.
Yamaguchi Y, Yamaue H, Okusaka T, Okuno K, Suzuki H, Fujioka T, Otsu A, Ohashi Y, Shimazawa R, Nishio K, Furuse J, Minami H, Tsunoda T, Hayashi Y, Nakamura Y. Cancer Sci. 2014 Jul;105(7):924-31. doi: 10.1111/cas.12443.

KIAA1199 interacts with glycogen phosphorylase kinase b-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.
Terashima M, Fujita Y, Togashi Y, Sakai K, Marco A. De Velasco, Shuta Tomida, Kazuto Nishio. Oncotarget. 2014 Aug 30;5(16):7040-50.

Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells.
Kim H, Terazono H, Nakamura Y, Sakai K, Hattori A, Odaka M, Girault MA, Arao T, Nishio K, Miyagi K, Yasuda K. PLoS One. 2014 Aug 20;9(8):e104372. doi: 10.1371/journal.pone.0104372. eCollection 2014.

Clinical utility of erlotinib for the treatment of non-small cell lung cancer in Japanese patients: current evidence.
Togashi Y, Hayashi H,Nakagawa, K, Nishio K. Drug Des Devel Ther. 2014 Jul 31;8:1037-46.

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter.
Sakai K, Takeda M, Okamoto I, Nagakawa K, Nishio K. Oncology Letter. 9(1): 405-410, 2015 Jun

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. BMC Cancer. 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530.

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer.
Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K. PLoS One. 2014 Jul 10;9(7):e102436

Androgen Deprivation Induces Phenotypic Plasticity and Promotes Resistance to Molecular Targeted Therapy in a PTEN-deficient Mouse Model of Prostate Cancer.
De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H. Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.
Yosuke Togashi, Hiroki Sakamoto, Hidetoshi Hayashi, Masato Terashima, Marco A de Velasco, Yoshihiko Fujita, Yasuo Kodera, Kazuko Sakai, Shuta Tomida, Masayuki Kitano, Akihiko Ito, Masatoshi Kudo and Kazuto Nishio. Mol Cancer. 2014 May 27;13:126. doi: 10.1186/1476-4598-13-126.

Multiplexed genomic profiling of non-small-cell lung cancers (NSCLC) from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Isamu Okamoto, Kazuko Sakai, Satoshi Morita, Hiroshige Yoshioka, Hiroyasu Kaneda, Koji Takeda, Tomonori Hirashima, Yoshihito Kogure, Tatsuo Kimura, Toshiaki Takahashi, Shinji Atagi, Takashi Seto, Toshiyuki Sawa, Masashi Yamamoto, Miyako Satouchi, Motoyasu Okuno, Seisuke Nagase, Koichi Takayama, Keisuke Tomii, Tadashi Maeda, Satoshi Oizumi, Shinji Fujii, Yusaku Akashi, Kazumi Nishino, Noriyuki Ebi, Kazuhiko Nakagawa, Yoichi Nakanishi, and Kazuto Nishio. Oncotarget. 2014 Apr 30;5(8):2293-304.

Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.
Fujita Y, Koinuma S, De Velasco MA, Bolz J, Togashi Y, Terashima M, Hayashi H, Matsuo T, Nishio K. PLoS One. 2014 Apr 10;9(4):e94772. doi: 10.1371/journal.pone.0094772. eCollection 2014.

Potential Anti-angiogenesis Effects of p-Terphenyl Compounds from Polyozellus multiplex.
Nagasawa I, Kaneko A, Suzuki T, Nishio K, Kinoshita K, Shiro M, Koyama K. J Nat Prod. 2014 Apr 25;77(4):963-8. doi: 10.1021/np401046z. Epub 2014 Mar 6.

Analytical Performance of the cobas EGFR Mutation Assay for Japanese Non-Small-Cell Lung Cancer Lung Cancer.
Kimura H, Ohira T, Uchida O, Matsubayashi J, Shimizu S, Nagao T, Ikeda N, Nishio K. Lung Cancer. 2014 Mar;83(3):329-33. doi: 10.1016/j.lungcan.2013.12.012.